micro-community-banner
 
Profile Image
  • Add Media
  • Saved

1yr
PCSK9 Inhibition With Orally Administered NNC0385-0434 in Hypercholesterolaemia: a Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial

PCSK9 Inhibition With Orally Administered NNC0385-0434 in Hypercholesterolaemia: a Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38310920/

Novo Nordisk.

The estimated treatment difference between NNC0385-0434 100 mg and evolocumab 140 mg was 3.4%.

Profile Image
  • Saved

1yr
An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis

An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis

Source : https://pubmed.ncbi.nlm.nih.gov/38593947/

An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns.

The "inclisiran first" strategy led to significantly greater reductions in LDL-C from baseline to day 330 versus usual care.

Profile Image
  • Saved

1yr
A Wrap Up of The American College of Cardiology 2024 Scientific Session

This year’s meeting marked the 75th anniversary of ACC and included practice-changing information on the prevention, diagnosis, and treatment of the full spectrum of cardiovascular diseases. Click to access our postconference wrap-up report.

  • Saved

1yr
Cardiovascular Risk Factors and Complications in Patients With Systemic Lupus Erythematosus With and Without Nephritis: a Systematic Review and Meta-Analysis

Cardiovascular Risk Factors and Complications in Patients With Systemic Lupus Erythematosus With and Without Nephritis: a Systematic Review and Meta-Analysis

Source : https://pubmed.ncbi.nlm.nih.gov/38519060/

CRD42022314682.

Patients with systemic lupus erythematosus and lupus nephritis showed significantly higher risk of hypertension, hyperlipidemia, and type 2 diabetes compared with those without lupus nephritis.

Profile Image
  • Saved

1yr
Primary and Secondary Prevention of Stroke and Cardiovascular Events Using Evolocumab and Alirocumab: Meta-Analysis of Randomized Controlled Trials

Primary and Secondary Prevention of Stroke and Cardiovascular Events Using Evolocumab and Alirocumab: Meta-Analysis of Randomized Controlled Trials

Source : https://pubmed.ncbi.nlm.nih.gov/38529927/

Our findings indicate that evolocumab and alirocumab are significantly effective without increasing the risk of hemorrhagic stroke. Based on this, the PCSK9 inhibitors can be highly recommended for cholesterol management.

These findings indicate that evolocumab and alirocumab are significantly effective without increasing the risk of hemorrhagic stroke.

Profile Image